Prof. Dr. Frank G. Holz, Schriftführer der DOG
Wir möchten in diesem Jahr Jean‑Frédéric Chibret für seine besonderen Verdienste mit der Theodor-Leber Medaille auszeichnen, dazu möchte ich ihn in Englisch vorstellen.
As many of you know, the Chibret Medal has been awarded to young German and French ophthalmologists to promote cooperation and exchange between the two countries for over 40 years, sponsored by Théa Pharma. The Paul Chibret Medal is intended to honor the best researchers in the field of ophthalmology who are willing and able to contribute to European cooperation in ophthalmology.
Laboratoires Théa was founded in 1994 by Henri Chibret. Jean-Frédéric Chibret joined in the early 2000s, after obtaining his MBA, and officially took over the operational management of Théa in 2008.
Under Jean-Frédéric’s leadership, Théa experienced rapid growth: modernization of production facilities, intensification of research efforts, international knowledge transfer, and the establishment of new subsidiaries, first in Europe and later worldwide. Today, Théa is one of the few French pharmaceutical companies with a presence in all four corners of Europe, before establishing itself in Africa, the Middle East, and the Americas. The company’s products are now distributed in more than 75 countries.
Jean‑Frédéric Chibret stands as a living testament to a 150‑year legacy of ocular excellence, seamlessly blending the weight of tradition with an unmistakable drive for innovation. He is the fourth‑generation heir of a family that has dedicated itself to advancing eye care. The Chibret lineage began with pioneering work in ophthalmology, notably with Jacques Chibret’s introduction of the world’s first YAG laser (1941‑1989). Today, Jean‑Frédéric embodies that same pioneering spirit, guiding the family’s enterprise into the modern era while honoring its historic roots.
Beyond commercial success, Jean‑Frédéric’s leadership exemplifies a rare synergy of heritage and progress. He honors the “promise of his ancestors”—the commitment to scientific rigor and patient‑centered care—while relentlessly pursuing new horizons in ophthalmic therapy. This dedication was formally recognized in 2022 when he received the Ernst & Young Entrepreneur of the Year award in France, a testament to his visionary management and entrepreneurial excellence. .